Get the Stockscreener App
44.21
0.43%
0.19
After Hours:
44.21
Moonlake Immunotherapeutics stock is traded at $44.21, with a volume of 316.24K.
It is up +0.43% in the last 24 hours and up +14.71% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$44.02
Open:
$43.36
24h Volume:
316.24K
Relative Volume:
0.60
Market Cap:
$2.98B
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-19.22
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
-5.70%
1M Performance:
+14.71%
6M Performance:
-13.89%
1Y Performance:
+3.51%
1-Day Range:
$42.97
$44.43
1-Week Range:
$42.31
$47.57
52-Week Range:
$31.42
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
44.21 | 2.98B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Developments - geneonline.com
MoonLake Immunotherapeutics’ SWOT analysis: nanobody firm’s stock poised for pivotal phase III data - Investing.com Nigeria
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga
IIH interview: Matthias Bodenstedt discusses MoonLake’s capital raising journey, the appeal of SLK and plans for the future - Investors in Healthcare
MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating - TipRanks
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Focus on Inflammatory Disease Treatments - geneonline.com
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Focus - geneonline.com
MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News - GuruFocus
Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics - TipRanks
StockWatch: Report of $3B+ Merck Buyout Offer Propels MoonLake Stock Surge - Genetic Engineering and Biotechnology News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Strategic Uncertainty - geneonline.com
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN
MoonLake Immunotherapeutics Elects Directors at AGM - TipRanks
Merck held talks to buy biotech MoonLake for over $3 billion - MSN
These Stocks Moved the Most Today: Nvidia, Tesla, Dollar General, Credo, Ferguson, Moonlake, and More - MSN
MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Industry Speculation - geneonline.com
A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions - insights.citeline.com
MoonLake Immunotherapeutics Reportedly Considering Sale Amid Competitive Pharmaceutical Market Challenges - geneonline.com
MoonLake Immunotherapeutics is for sale? This sounds like a cry for help - statnews.com
Merck's Bold Proposal Sends MoonLake's Shares Climbing - Finimize
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Two Biotechs That Could Get an M&A Boost - TheStreet Pro
Merck & Co., Inc. (MRK) Held Talks Over $3 Billion Acquisition of Swiss Biotech Firm MoonLake - MSN
Merck in Talks to Acquire MoonLake Immunotherapeutics for $3 Billion - geneonline.com
MSD rumoured to be eyeing $3bn+ MoonLake takeover - pharmaphorum
MoonLake Immunotherapeutics (MLTX) Surges 25% on Merck Acquisiti - GuruFocus
MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid - Investor's Business Daily
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest (MLTX) - Seeking Alpha
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Shifts - geneonline.com
MoonLake Immunotherapeutics Breaks Above 200-Day Moving AverageBullish for MLTX - Nasdaq
MoonLake's (MLTX) 'Outperform' Rating Reiterated by RBC Capital - GuruFocus
MoonLake takeover thesis reemerges after FT report, says Citi - TipRanks
MoonLake Shares Jump On Potential Merck Acquisition Offer - Finimize
MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating - TipRanks
RBC Capital maintains outperform rating on Moonlake stock By Investing.com - Investing.com India
RBC Capital maintains outperform rating on Moonlake stock - Investing.com
Long Term Trading Analysis for (MLTX) - news.stocktradersdaily.com
Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FT - Fierce Biotech
Guggenheim reaffirms Buy rating on Moonlake stock amid M&A talks By Investing.com - Investing.com South Africa
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports - MSN
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):